ISIS 681257

DRUG4 trials

Sponsors

Akcea Therapeutics

Conditions

Cardiovascular DiseaseCardiovascular DiseasesElevated Lipoprotein(a)Renal Impairment

Phase 1

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

CompletedNCT03392051

Akcea TherapeuticsCardiovascular Diseases, Elevated Lipoprotein(a)

Start: 2017-12-28End: 2018-03-18Updated: 2018-04-05

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

CompletedNCT03426033

Akcea TherapeuticsCardiovascular Diseases, Elevated Lipoprotein(a)

Start: 2017-12-15End: 2018-02-25Updated: 2018-04-05

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

CompletedNCT03506854

Akcea TherapeuticsRenal Impairment

Start: 2018-03-20End: 2018-10-11Updated: 2019-05-22

Phase 2

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

CompletedNCT03070782

Akcea TherapeuticsCardiovascular Disease, Elevated Lipoprotein(a)

Start: 2017-03-07End: 2018-11-13Updated: 2020-10-30

Related Papers

Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)

European Heart Journal2020-02-27111 citations

Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease.

2020-02-1126 citations

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

New England Journal of Medicine2020-01-01921 citations